AstraZeneca: FDA approves label update for lung cancer drug

(CercleFinance.com) - The FDA has approved AstraZeneca to update the label for its immunotherapy Imfinzi to include survival data from a Phase III trial in patients with late-stage non-small cell lung cancer.


The label update is based on results which showed a significant and clinically-proven overall survival benefit for treatment with Imfinzi vs. placebo in this setting, reducing the risk of death by 32%.

Imfinzi is approved for the treatment of unresectable, stage III non-small cell lung cancer in over 45 countries, including the US, EU and Japan.

Copyright (c) 2019 CercleFinance.com. All rights reserved.